P21, also widely referenced as P021 in academic papers, is an artificially engineered peptidomimetic derived from the bioactive fragment of ciliary neurotrophic factor (CNTF). Unlike native large?size CNTF protein, this molecule carries two key terminal modifications: N?terminal acetylation and C?terminal adamantyl?glycine grafting. The adamantyl group raises lipophilic character to assist membrane penetration, meanwhile shielding peptide terminals against exopeptidase breakdown in biological environments. Its compact molecular dimension makes it a unique tool for central nervous system?oriented pre?clinical exploration.

Modification sites bring extra challenges for quality assessment; incomplete adamantylation and de?acetylated by?products need strict tracking during production. Mass spectrometry is adopted to confirm full modified molecular weight rather than only bare peptide backbone, while HPLC separates partially modified impurities to guarantee experimental reliability. This compound is largely deployed for hippocampal neurogenesis observation, tau?pathology related neurodegeneration models, BDNF?associated signal pathway analysis and brain injury mechanistic researchPMC.

Due to its hybrid lipophilic?hydrophilic property, avoid vigorous shaking while preparing stock solutions to prevent unexpected molecular aggregation. Lyophilized powder keeps stable under frozen dark sealed storage. Once reconstituted, prepare divided single?use aliquots. Repeated freeze?thaw cycles may trigger modification?group loss and compromise assay consistency.